Tenorio G, García RM

Language: Spanish
References: 33
Page: 136-141
PDF size: 76.60 Kb.

ABSTRACT

Introduction: The pars planitis is an idiopathic inflammation of the base of vitreous and the peripheral retina (intermedial uveitis), asymptomatic until late stages or severe inflammation, its treatment is based on the use of steroids. Its biggest complication it is the development of secondary glaucoma. Rimexolone is a topical steroid not associated with increase in the intraocular pressure during its chronic use. Objective: To evaluate the safety in the intraocular pressure in patient with pars planitis and therapy with rimexolone as well as to determine its effect antiinflamatory. Method: It´s a retrospective, longitudinal, comparative and descriptive investigation, analyzing the files of patient with pars planitis of the Hospital General of Mexico. The intraocular pressure and inflammation were evaluated in 2 groups: 1) rimexolone 4 times/day for a year and 2) other topical steroid for the same time. Results: The files were evaluated, from January of 1997 to August of 2003, dividing them in two comparative groups: rimexolone (12 patients, 29%) other steroid (15 patients, 37%). PIO was evaluated in patient with rimexolone (13.25 mm Hg initial and final average 12.5 mm Hg) and in patient to who another steroid was applied (13.13 mm Hg initial and final average 17 mm Hg). The statistic analysis was made with t Student test (2.17, significative) and χ² for inflammation (rimexolone 7.28, no significative and other 22.88, significative). Conclusions: We confirm that the rimexolone is a topical steroid with appropriate control in the safety of the intraocular pressure in patient with active pars planitis.

REFERENCES

1. Hathaway WE. Diagnóstico y tratamiento pediátrico. 8a ed. México: Manual Moderno, 1995; 502-503.

2. Tierney LM. Diagnóstico clínico y tratamiento. México: Manual Moderno, 1999; 193-194.

3. Kanski J. Oftalmología clínica. 4a ed. España: Harcourt, 2000; 273-275.

4. Stambury R, Wallace G, Graham E. Retinal Vascular Desorders: Intermediate uveitis. Pars planitis, multiple sclerosis and retinal vasculitis. Ophthalmol Clin N Am 1998; 11 (4): 78-89.

5. Nussemblatt R, Palestine A. Uveitis: Fundamentals and clinical practice. USA: Year Book Medical Publisher, 1989; 185-197.

6. Schachat A, Murphy R. Dugel D, Smith R. Retina. Cap 99: Pars planitis. 2nd ed. USA: Mosby, 1982; 1621-1630.

7. Glaucoma, Lens and Anterior Segment. Basic and Clinical Science Course. USA: Am Acad of Ophthalmol, 1987-1988; 64-65.

8. Pediatric ophthalmology and strabismus. Basic and Clinical Science Course. USA: Am Acad of Ophthalmol, 1998; 6: 258-259.

9. Belfort R, Couto C, Martínez-Castro F. Uveítis. Sinopsis diagnóstica y terapéutica. Cap 18: Pars planitis. México: Ciba Visión Novartis Co, 1997; 134-141.

10. Orucs DB, Vohanakent et al. The association of HLA class II with pars planitis. Am J Ophthalmol 2003; 133 (5): 657-659.

11. Intraocular inflammation uveitis and ocular tumors. Basic and Clinical Science Course. USA: Am Acad of Ophthalmol, 1987-1988; 3: 108-111.

12. Jordan J, Walter P, Ayertey H, Brunner R. Intermediate uveitis in childhood preceding the diagnosis of multiple sclerosis: A 13 year follow-up. Brief report. Am J Ophthalmol 2003; 133 (6): 885-886.

13. Klok A, Luyendijk L, Zaal M, Rothova A, Kiljstra A. Soluble ICAM-1 serum levels in patients with intermediate uveitis. Br J Ophthalmol 1999; 83: 847-751.

14. Nelson LD. Oftalmología pediátrica. 4a ed. México: McGraw-Hill-Interamericana, 2000; 241-345.

15. Morse P. Vitreoretinal disease and treatment. EUA: Year Book Medice Publisher, 1979; 540.

16. Riordan PE. Glaucoma. En: Vaughan and Asbury. Oftalmología general. 13a ed. México: Manual Moderno, 2004: 250.

17. Leibowitz H, Basrtlett J, Richich R et al. Intraocular pressure-raising potential of 1.0% rimexolone in patients responding to corticosteroids. Arch Ophthalmol 1996; 114 (8): 1000–1001.

18. Raizman M. Corticosteroid therapy of eye disease. Fifty years later. Arch Ophthalmol 1996; 114 (8): 933-937.

19. Chipont B. Cunningham Jr. Manejo del paciente con uveítis anterior aguda. Arch Soc Esp 2002; 4: 95-105.

20. Meier F et al. Cataract surgery in uveitis. Ophthalmol Clin N Am 2002; 15 (3): 72-77.

21. Schere H, Albert D. Textbook of ophthalmology. 9th ed Canadá: Saunders, 1977; 24.

22. Rhee D. Pyfer M. Manual de urgencias oftalmológicas. The Wills Eye Hospital. 3a ed. México: McGraw-Hill-Interamericana, 2002; 457-459.

23. Kok H, Barton K. Uveitic glaucoma; Ophthalmol Clin N Am 2002; 15 (3): 35-37.

24. Alward W. Glaucoma: Los requisitos en oftalmología. España: Mosby-Harcourt, 2001; 138-139.

25. Ghandler C, Epstein D. Glaucoma. 3th ed. USA: Lea and Febiger, 1986; 376.

26. Darrin L, Dennis P, Sundeep D et al. Subtenon´s depot corticosteroid injections in patiens with history of corticosteroid induced intraocular pressure elevation. Am J Ophthalmol 2002; 133 (2): 196-202.

27. Fredman S, Rodriguez R, Rojas M, Enyedil L. Goniotomy for glaucoma secondary to chronic childhood uveitis. Am J Ophthalmol 2002; 133 (5): 617-621.

28. Rodríguez CR, Tenorio G. Vademécum académico de medicamentos oftalmológicos UNAM. México: MacGraw-Hill, 2002: 52-53.

29. Fernández A, Povedanos J, Campos S et al. Eficacia Clínica de la infiltración con esteroides. Rev FSP Reumatol 1998; 25: 361-370.

30. Halper MT, Palmer CS, Foster S, Pal A, Battista C. A pharmacoeconomic analysis of rimexolone for the treatment of ophthalmic inflammatory conditions. Am J Manag Care 1998; 4 (6): 854-862.

31. Foster S, Aletr G, Debarge R et al. Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol 1996; (2): 171-182.

32. Biswas J, Ganeshbabu TM, Raghavendran SR, Raizada S, Mondkar SV, Madhavan HN. Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis. A randomized triple masked study. Int Ophthalmol 2004; 25 (3): 147-153.

33. Fan Ds, Yu CB, Chin TY, Wong CY, NgJS, Pang CP, Lam DS. Ocular hypertensive and antiinflammatory response to rimexolone therapy in children. Arch Ophthalmol 2003; 121 (12): 1716-1721.